Generic Cleviprex Availability
Last updated on Oct 9, 2024.
Cleviprex is a brand name of clevidipine, approved by the FDA in the following formulation(s):
CLEVIPREX (clevidipine - emulsion;intravenous)
-
Manufacturer: CHIESI
Approval date: August 1, 2008
Strength(s): 25MG/50ML (0.5MG/ML) [RLD], 50MG/100ML (0.5MG/ML) [RLD] -
Manufacturer: CHIESI
Approval date: November 8, 2013
Strength(s): 125MG/250ML (0.5MG/ML) (discontinued) [RLD]
Has a generic version of Cleviprex been approved?
No. There is currently no therapeutically equivalent version of Cleviprex available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cleviprex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Clevidipine emulsion formulations containing antimicrobial agents
Patent 10,010,537
Issued: July 3, 2018
Inventor(s): Motheram Rajeshwar & Williams Gregory Charles
Assignee(s): Chiesi Farmaceutici S.p.A.Pharmaceutical formulations comprising clevidipine and an antimicrobial agent exhibit a reduced propensity for microbial growth and provide increased convenience to health care workers administering clevidipine-containing formulations to patients.
Patent expiration dates:
- October 10, 2031✓
- October 10, 2031
-
Clevidipine emulsion formulations containing antimicrobial agents
Patent 11,103,490
Issued: August 31, 2021
Inventor(s): Motheram Rajeshwar & Williams Gregory Charles
Assignee(s): CHIESI FARMACEUTICI S.P.A.Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
Patent expiration dates:
- October 10, 2031✓
- October 10, 2031
-
Clevidipine emulsion formulations containing antimicrobial agents
Patent 8,658,676
Issued: February 25, 2014
Inventor(s): Motheram Rajeshwar & Williams Gregory Charles
Assignee(s): The Medicines CompanyPharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
Patent expiration dates:
- October 10, 2031✓
- October 10, 2031
More about Cleviprex (clevidipine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: calcium channel blockers
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.